Regular paperImpact of age and sex on plasma natriuretic peptide levels in healthy adults☆
Section snippets
Study sample:
The selection criteria and design of the Framingham Heart Study have been described previously.7 The offspring cohort began in 1971 with the recruitment of 5,124 men and women who were offspring or spouses of the offspring of the original Framingham cohort. The 3,532 participants who attended the sixth offspring examination cycle (1995 to 1998) were eligible for the present investigation. All attendees underwent routine physical examination (with a medical history), laboratory assessment of
Results
Characteristics of the subjects in the reference sample are displayed in Table 1. Mean age was 55 years, and 62% were women. Compared with men, women had higher mean levels of BNP and NT-ANP (both p ≤0.0001).
Impact of gender on natriuretic peptide levels:
Women had markedly higher natriuretic peptide levels than men, a finding that has been reported by several other investigators.11, 12, 13 The physiologic basis for these sex-related differences is unclear, although the stimulatory effect of female sex hormones on natriuretic peptide gene expression14 and extracardiac sources of natriuretic peptides within the female reproductive tract have been proposed.15 It is notable that a sexual dimorphism in plasma renin levels also exists, with higher
Acknowledgements
We would like to thank Marc A. Pfeffer, MD, PhD, and Hisako Tsuji, MD, for their valuable input. In addition, Shionogi & Co., Ltd. provided important assistance and performed the natriuretic peptide assays.
References (29)
- et al.
Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left-ventricular dysfunction
Lancet
(1993) - et al.
Biochemical detection of left-ventricular systolic dysfunction
Lancet
(1998) - et al.
Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care
Lancet
(1997) - et al.
Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction
Am Heart J
(2001) - et al.
Atrial natriuretic peptide and blood pressure in a population-based sample
Mayo Clin Proc
(1995) - et al.
Raised circulating levels of atrial natriuretic peptides in essential hypertension
Lancet
(1986) - et al.
Natriuretic peptides
N Engl J Med
(1998) - et al.
Circulating N-terminal pro-atrial natriuretic peptide is an independent predictor of left ventricular hypertrophy in the general populationThe Tromso Study
Eur Heart J
(1999) - et al.
An investigation of coronary heart disease in familiesthe Framingham Offspring Study
Am J Epidemiol
(1979) - et al.
Recommendations regarding quantitation in M-mode echocardiographyresults of a survey of echocardiographic measurements
Circulation
(1978)
On dividing reference data into subgroups to produce separate reference ranges
Clin Chem
Approved recommendations (1987) on the theory of reference values. Vstatistical treatment of collected reference values. Determination of reference limits
J Clin Chem Biochem
The influence of gender, age, and the menstrual cycle on plasma atrial natriuretic peptide
J Clin Endocrinol Metab
Significance of brain natriuretic peptide measurement as a diagnostic indicator of cardiac function
Methods Inf Med
Cited by (426)
Circulating cardiovascular biomarkers during and after preeclampsia: Crosstalk with placental function?
2022, Pregnancy HypertensionNT-proBNP and predictors of event free survival and left ventricular systolic function recovery in peripartum cardiomyopathy
2022, International Journal of Cardiology2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
2022, Journal of the American College of CardiologyActive B-Type Natriuretic Peptide Measured by Mass Spectrometry and Response to Sacubitril/Valsartan
2021, Journal of Cardiac Failure
- ☆
This work was supported in part by Contracts N01-HC-25195, R01 HL64753, R01-NS-17950, and 1R01HL67288-01 and Dr. Vasan was supported by Contract K24 HL 04334-01A1 from the National Institutes of Health/National Heart, Lung, and Blood Institute, Bethesda, Maryland.